Fig. 1From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinomaRadiologic response to the combination therapy of TACE and sorafenib, which was assessed based on the mRECIST criteria after first TACEBack to article page